BDX Stock Recent News

Becton, Dickinson and Company (BD) experienced weak growth in China, with a decline of 5.3% year-over-year. BD's major challenges, including the Alaris pump and Covid comparisons, are starting to normalize. The stock price is undervalued, leading to an upgrade in rating from 'Hold' to 'Buy' with a fair value of $250 per share.

The stock market bulls are charging right now. The Federal Reserve appears set to lower interest rates this year, which could stoke equity markets.

BD (BDX) collaborates with Camtech Health to improve the rate of cervical cancer screening in Singapore by offering women an option to self-collect samples in the privacy of their own homes.

Investors looking for stocks in the Medical - Dental Supplies sector might want to consider either Becton Dickinson (BDX) or West Pharmaceutical Services (WST). But which of these two stocks is more attractive to value investors?

FRANKLIN LAKES, N.J. , Feb. 12, 2024 /PRNewswire/ -- BD (Becton, Dickinson and Company) (NYSE: BDX), a leading global medical technology company, today announced that it will present the next installment of its BD Innovates series — which will highlight BD solutions that help clinicians treat Peripheral Vascular Disease — on Monday, February 26, 2024, at 3:00 PM Eastern Time.

BD's (BDX) slew of product launches raises optimism about the stock.

Becton, Dickinson and Company (BDX) Q1 2024 Earnings Call Transcript

BD's (BDX) overall top line benefits from revenue growth in the majority of its segments and both geographic regions in the fiscal first quarter.

While the top- and bottom-line numbers for Becton Dickinson (BDX) give a sense of how the business performed in the quarter ended December 2023, it could be worth looking at how some of its key metrics compare to Wall Street estimates and year-ago values.

Becton Dickinson (BDX) came out with quarterly earnings of $2.68 per share, beating the Zacks Consensus Estimate of $2.39 per share. This compares to earnings of $2.98 per share a year ago.